Selective CDK9 degradation using a proteolysis-targeting chimera (PROTAC) strategy

References

• 1. Blake DR, Vaseva AV, Hodge RG et al. Application of a MYC degradation screen identifies sensitivity to CDK9 inhibitors in KRAS-mutant pancreatic cancer. Sci. Signal. 12(590), eaav7259 (2019).
  MedlineGoogle Scholar
• 2. Sonawane YA, Taylor MA, Napoleon JV, Rana S, Contreras JI, Natarajan A. Cyclin dependent kinase 9 inhibitors for cancer therapy. J. Med. Chem. 59(19), 8667–8684 (2016).
  Medline CASGoogle Scholar
• 3. Sakamoto KM, Kim KB, Kumagai A, Mercurio F, Crews CM, Deshaies RJ. Protacs: chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation. Proc. Natl Acad. Sci. USA 98(15), 8554–8559 (2001).
  Medline CASGoogle Scholar
• 4. Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. Nat. Rev. Cancer 9(3), 153–166 (2009).
  Medline CASGoogle Scholar
• 5. Rana S, Mallareddy JR, Singh S et al. Inhibitors, PROTACs and molecular glues as diverse therapeutic modalities to target cyclin dependent kinase. Cancers 13, 5506 (2021).
  MedlineGoogle Scholar
• 6. Martin MP, Endicott JA, Noble MEM. Structure-based discovery of cyclin-dependent protein kinase inhibitors. Essays Biochem. 61(5), 439–452 (2017).
  MedlineGoogle Scholar
• 7. Hirose Y, Ohkuma Y. Phosphorylation of the C-terminal domain of RNA polymerase II plays central roles in the integrated events of eucaryotic gene expression. J. Biochem. 141(5), 601–608 (2007).
  Medline CASGoogle Scholar
• 8. Chen R, Keating MJ, Gandhi V, Plunkett W. Transcription inhibition by flavopiridol: mechanism of chronic lymphocytic leukemia cell death. Blood 106(7), 2513–2519 (2005).
  Medline CASGoogle Scholar
• 9. Chen R, Guo L, Chen Y, Jiang Y, Wierda WG, Plunkett W. Homoharringtonine reduced Mcl-1 expression and induced apoptosis in chronic lymphocytic leukemia. Blood 117(1), 156–164 (2011).
  Medline CASGoogle Scholar
• 10. Lee DJ, Zeidner JF. Cyclin-dependent kinase (CDK) 9 and 4/6 inhibitors in acute myeloid leukemia (AML): a promising therapeutic approach. Expert Opin. Investig. Drugs 28(11), 989–1001 (2019).
  Medline CASGoogle Scholar
• 11. Wu T, Qin Z, Tian Y et al. Recent developments in the biology and medicinal chemistry of CDK9 inhibitors: an update. J. Med. Chem. 63(22), 13228–13257 (2020).
  Medline CASGoogle Scholar
• 12. Robb CM, Contreras JI, Kour S et al. Chemically induced degradation of CDK9 by a proteolysis targeting chimera (PROTAC). Chem. Commun. (Camb.) 53(54), 7577–7580 (2017).
  Medline CASGoogle Scholar
• 13. King HM, Rana S, Kubica SP et al. Aminopyrazole based CDK9 PROTAC sensitizes pancreatic cancer cells to venetoclax. Bioorg. Med. Chem. Lett. 43, 128061 (2021).
  Medline CASGoogle Scholar
• 14. Olson CM, Jiang B, Erb MA et al. Pharmacological perturbation of CDK9 using selective CDK9 inhibition or degradation. Nat. Chem. Biol. 14(2), 163–170 (2018).
  Medline CASGoogle Scholar
• 15. Bian J, Ren J, Li Y et al. Discovery of wogonin-based PROTACs against CDK9 and capable of achieving antitumor activity. Bioorg. Chem. 81, 373–381 (2018).
  Medline CASGoogle Scholar
• 16. Lu J, Qian Y, Altieri M et al. Hijacking the E3 ubiquitin ligase cereblon to efficiently target BRD4. Chem. Biol. 22(6), 755–763 (2015).
  Medline CASGoogle Scholar
• 17. Hu B, Zhou Y, Sun D et al. PROTACs: new method to degrade transcription regulating proteins. Eur. J. Med. Chem. 207, 112698 (2020).
  Medline CASGoogle Scholar
• 18. Contreras JI, Robb CM, King HM et al. Chemical genetic screens identify kinase inhibitor combinations that target anti-apoptotic proteins for cancer therapy. ACS Chem. Biol. 13(5), 1148–1152 (2018).
  Medline CASGoogle Scholar
• 19. Moreau K, Coen M, Zhang AX et al. Proteolysis-targeting chimeras in drug development: a safety perspective. Br. J. Pharmacol. 177(8), 1709–1718 (2020).
  Medline CASGoogle Scholar
• 20. Qiu X, Li Y, Yu B et al. Discovery of selective CDK9 degraders with enhancing antiproliferative activity through PROTAC conversion. Eur. J. Med. Chem. 211, 113091 (2021).
  Medline CASGoogle Scholar